Plasma Proteomics and Immunopeptidomics: Expert Solutions for Real-World Research Challenges

Biognosys, in partnership with PreOmics, showcases the latest advances in mass spectrometry–based plasma proteomics and immunopeptidomics. A pilot study using P2 Plasma Enrichment Technology explores circulating biomarkers predictive of treatment response in breast cancer, complementing insights from Olink. Two immunopeptidomics studies with Spectronaut 20 reveal kinase-regulated tumor antigens in chronic myeloid leukemia and show how ERAP1 inhibition reshapes the HLA-B*27:05 immunopeptidome in autoimmunity. Join us to explore these cutting-edge technologies and their translational impact on biomarker discovery.